ResMed Inc.
General ticker "RSMDF" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $39.8B (TTM average)
ResMed Inc. does not follow the US Stock Market performance with the rate: -6.6%.
Estimated limits based on current volatility of 1.2%: low 27.33$, high 27.97$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-11-13, amount 0.06$ (Y0.88%)
- Total employees count: 229 as of 1996
- US accounted for 63.6% of revenue in the fiscal year ended 2024-06-30
- Earnings for 15 months up through Q1 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-06-30 to 2026-06-30
- 2024-06-30 to 2025-06-30 estimated range: [18.00$, 25.14$]
- 2025-06-30 to 2026-06-30 estimated range: [19.83$, 27.59$]
Financial Metrics affecting the RSMDF estimates:
- Positive: with PPE of 25.2 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 28.17 > 18.64
- Positive: Operating cash flow per share per price, % of 53.85 > 13.24
- Positive: Return on assets ratio (scaled to [-100,100]) of 12.93 > 6.04
- Positive: Shareholder equity ratio, % of 70.78 > 63.39
- Negative: Industry operating cash flow per share per price (median), % of 0.52 <= 5.52
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: -8.75 < Industry operating profit margin (median), % of -7.29
- Positive: Interest expense per share per price, % of 1.76 <= 3.41
- Positive: -14.38 < Investing cash flow per share per price, % of -10.37
Short-term RSMDF quotes
Long-term RSMDF plot with estimates
Financial data
| YTD | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating Revenue | $4,222.99MM | $4,685.30MM | $5,146.33MM |
| Operating Expenses | $3,091.12MM | $3,365.40MM | $3,460.96MM |
| Operating Income | $1,131.87MM | $1,319.89MM | $1,685.36MM |
| Non-Operating Income | $-30.21MM | $-55.09MM | $-7.80MM |
| Interest Expense | $47.38MM | $45.71MM | $12.61MM |
| R&D Expense | $287.64MM | $307.52MM | $331.28MM |
| Income(Loss) | $1,101.66MM | $1,264.80MM | $1,677.57MM |
| Taxes | $204.11MM | $243.85MM | $276.84MM |
| Profit(Loss)* | $897.56MM | $1,020.95MM | $1,400.72MM |
| Stockholders Equity | $4,129.90MM | $4,864.04MM | $5,967.86MM |
| Inventory | $998.01MM | $822.25MM | $927.71MM |
| Assets | $6,751.71MM | $6,872.39MM | $8,174.39MM |
| Operating Cash Flow | $693.30MM | $1,401.26MM | $1,751.59MM |
| Capital expenditure | $134.00MM | $114.86MM | $89.86MM |
| Investing Cash Flow | $-1,159.85MM | $-269.78MM | $-200.04MM |
| Financing Cash Flow | $422.87MM | $-1,119.29MM | $-606.25MM |
| Earnings Per Share** | $6.12 | $6.94 | $9.55 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.